Astellas Pharma has been granted a patent for a pharmaceutical composition and method for treating cell death in a subject post-surgery by inhibiting poly(ADP-ribose)polymerase (PARP). The composition includes a specific compound and carrier. GlobalData’s report on Astellas Pharma gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Astellas Pharma, Cancer treatment biomarkers was a key innovation area identified from patents. Astellas Pharma's grant share as of May 2024 was 44%. Grant share is based on the ratio of number of grants to total number of patents.
Treating cell death in a subject after surgery
A recently granted patent (Publication Number: US11993585B2) discloses a method for treating cell death in a subject post-surgery by administering a specific compound or its pharmaceutically acceptable salt or composition. The compound is represented by a defined structural formula, and the administration can be done orally, as per the claims outlined in the patent.
The patent further details the specific structural formulas and configurations of the compound, including variations in substituents and functional groups. The method involves the selection of specific R groups and Ring B structures, as well as the presence of certain elements like halogens, alkyl groups, and cyano groups. Additionally, the patent specifies the compound's chemical structure, such as 6-[(3S)-4-[3-(6-fluoro-4-oxo-3H-quinazolin-2-yl)propanoyl]-3-methyl-piperazin-1-yl]pyridine-3-carbonitrile, as an example of the compound to be used in the treatment method. The detailed claims provide a comprehensive overview of the method and the specific compound involved in treating cell death in post-surgery subjects.
To know more about GlobalData’s detailed insights on Astellas Pharma, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
